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Abstract 
Following up the open initiative of anti-malarial drug discovery, a GlaxoSmithKline 
(GSK) phenotypic screening hit was developed to generate hydroxyethylamine based 
plasmepsin (Plm) inhibitors exhibiting growth inhibition of the malaria parasite 
Plasmodium falciparum at nanomolar concentrations. Lead optimization studies were 
performed with the aim of improving Plm inhibition selectivity versus the related 
human aspartic protease cathepsin D (Cat D). Optimization studies were performed 
using Plm IV as a readily accessible model protein, the inhibition of which correlates 
with anti-malarial activity. Guided by sequence alignment of Plms and Cat D, 
selectivity-inducing structural motifs were modified in the S3 and S4 sub-pocket 
occupying substituents of the hydroxyethylamine inhibitors. This resulted in potent 
anti-malarials with an up to 50-fold Plm IV/Cat D selectivity factor. More detailed 
investigation of the mechanism of action of the selected compounds revealed that they 
inhibit maturation of the P. falciparum subtilisin-like protease protease SUB1, and 
also inhibit parasite egress from erythrocytes. Our results indicate that the anti-
malarial activity of the compounds is linked to inhibition of the SUB1 maturase 
plasmepsin subtype Plm X.   
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1. Introduction 
Malaria is a life-threatening disease caused by Plasmodium parasites which are 
transmitted by mosquitoes.1 More than half of the earth’s population lives in malaria 
endemic areas, rendering the disease a global health problem. Extensive eradication 
campaigns have been implemented, leading to considerably reduced malaria 
morbidity.2 A key future goal, according to the Global Technical Strategy for Malaria 
2016–2030, is a 90% reduction in clinical cases and deaths by 2030 as compared with 
2015.3 However, these efforts are impeded by widespread resistance of the parasite to 
all currently used drugs, including artemisinins, the current front line drug class.4-6 
Consequently, new antimalarial drugs with new modes of action are urgently needed. 
Their development faces notable hurdles, one of which is a low expected profit after 
market approval. This has prompted several open innovation initiatives by private and 
academic organizations, including the disclosure of preclinical research data to the 
scientific community.7-10 To support one such initiative, GlaxoSmithKline (GSK) 
recently published the results of a large-scale cell-based (phenotypic) HTS screening 
campaign that provided a number of starting points for anti-malarial drug discovery.7 
From the pool of parasite growth inhibitory compounds we selected 
hydroxyethylamine derivative 1a for further development (Figure 1).11 In our 
previous studies we showed that compound 1a is an inhibitor of the Plasmodium 
falciparum aspartic proteases - plasmepsin subtypes Plm I, Plm II and Plm IV with 
particularly high potency against Plm IV. Structurally simplified potent Plm IV 
inhibitors 1b,c were developed as compound 1a analogues, retaining high potency in 
P. falciparum growth assays. 
Table 1. Representative Plm inhibitors 1a-c from previous studies11 
 
Comp. R 
IC50  
Plm IV, 
 
IC50 
 Cat D,  
EC50  
Pf growth,  
(S,R)-1a 
 
0.029 0.043 0.002 
(S,R)-1b 
 
0.024 0.042 0.006 
(S,R)-1c Ph 0.006 0.054 0.002 
It is important to note that despite more than two decades of research on plasmepsin 
inhibitor discovery, only a few compounds (including inhibitors 1a-c) exhibiting 
parasite growth inhibition at low nanomolar concentration have been identified.11,12  
This is likely attributable to the fact that most of the efforts so far have been devoted 
to inhibiting plasmepsin subtypes involved in hemoglobin digestion (Plms I-IV).13-22 
Gene disruption studies have revealed that none of these hemoglobinase Plms are 
essential in the parasite asexual blood stage lifecycle, indicating a high degree of 
redundancy in the hemoglobin catabolic pathway.23-25 In contrast, the three other 
plasmepsin subtypes expressed in the P. falciparum blood stages, Plms V,26-28  IX, 
and X,29-32 all appear to be essential for parasite viability. The hemoglobinase 
plasmepsins (Plm I, II, IV) share high sequence homology with Plms IX and X, but 
not Plm V. It might therefore be expected that inhibitors developed to target the 
hemoglobinase Plms would exhibit activity in cell-based assays only if they 
additionally target Plms IX and/or Plm X. Recombinant expression of both Plms IX 
and X has been recently reported,29,30 but this could be achieved only in higher 
eukaryotic protein expression systems, such as insect or mammalian cells. For our 
further work to develop the hydroxyethylamine based inhibitors (S,R)-1a-c as anti-
malarials we therefore used Plm IV as a readily accessible model plasmepsin, an 
approach also supported by the previously observed good correlation between  
inhibition of this enzyme and potency in parasite growth assays in erythrocytes.11,20 
The successful development of protease inhibitors as drugs requires optimization of 
on-target potency and minimization of undesirable off-target activity, particularly 
against related host proteases. The human lysosomal aspartic protease cathepsin D 
(Cat D) plays critical roles in protein catabolism and retinal function.33 Recent work 
focused on development of inhibitors of the human aspartic protease -secretase 
(BACE1) revealed the importance of ensuring selectivity against Cat D in order to 
avoid off-target ocular toxicity.34,35 In view of this, we decided that the next step for 
optimization of the hydroxyethylamine based Plm inhibitors 1 should aim to improve 
their selectivity for their malarial target(s) over human Cat D. 
2. Results and discussion 
2.1. Structural factors determining the selectivity of inhibitor binding to Plms vs 
Cat D 
Our previous SAR investigations revealed that the substituents of the inhibitor (S,R)-1 
occupying the prime sub-pockets (part S’, Table 1) are optimal for Plm inhibition.11 
Therefore, we focused our efforts on optimisation of selectivity inducing motifs in the 
substituents occupying the non-prime sub-pockets (Table 1). To assess the differences 
in inhibitor recognition between Plms IV, IX, X and Cat D, we generated a structure-
based sequence alignment of these proteins and compared their interactions with 
inhibitor 1b in docking models. Since Plm IX and X lack experimentally determined 
structures and in order to avoid possible inaccuracies associated with the use of 
homology models, the docking studies were performed on the crystal structure of Plm 
IV (PDB ID 2ANL), which is the closest homologue with an available crystal 
structure.36 As can be seen from Fig. 1A, the S3 sub-pocket shows the largest 
differences in amino acid composition between the Plms and Cat D. Additionally, this 
revealed that the S3 sub-pocket of Plm IV is wider, more shallow and more 
hydrophobic than that of Cat D (Fig. 1B). For these reasons, selectivity improvement 
was first attempted by modifying the N,N-dipropylamide moiety in inhibitors (S,R)-1 
which occupies the S3 sub-pocket.  
 
Fig. 1. (A) Structure-based sequence alignment of the amino acid residues making up 
the S1’ and S1-S4 pockets of Plm IV, Plm IX, Plm X and Cat D. (B) Surface 
representation of the S3 and S4 pockets in Plm IV and Cat D docking models with the 
hydroxyethylamine based inhibitor (S,R)-1b. The figure was prepared in PyMol.37 
Surface oxygen atoms are colored in red, nitrogens in blue, sulfurs in yellow and 
hydrogens and carbons in grey. 
  
Several N,N-disubstituted amide analogues (S,R)-2a,b,d-f were synthesized (see 
Section 2.3) bearing hydrophobic groups that would prefer the more hydrophobic S3 
sub-pocket of Plm IV. Unexpectedly the N,N-diethyl and N,N-dimethyl substituted 
analogues (S,R)-2a and (S,R)-2b showed the highest selectivity factor for Plm IV 
inhibition over Cat D, even though our docking studies indicated that the wider S3 
sub-pocket of Plm IV could accommodate bulkier groups. Analogue (S,R)-2c bearing 
N-hydroxyethyl groups showed 3-fold weaker Plm IV inhibition potency than 
compound (S,R)-2a. Introduction of larger linear substituents such as N,N-dipropyl 
(compound (S,R)-1b), N,N-di(methoxyethyl) (compound (S,R)-2d) and N,N-di(3,3,3-
trifluoropropyl) (compound (S,R)-2e) resulted in improved Cat D inhibition and 
correspondingly lower selectivity factors, suggesting that these groups fit well in the 
deep S3 sub-pocket of Cat D. Analogue (S,R)-2f bearing a N,N-diisobutyl amide 
showed poor inhibition of both enzymes, indicating that this group is too large to fit 
into the S3 sub-pocket of both Plm IV and Cat D. 
 
Table 2. SAR of N,N-disubstituted amide analogues (S,R)-1b, 2a-f 
 
Comp. R IC50 
Plm IV,  
IC50 
Cat D,  
Sa 
(S,R)-1b n-Pr 0.024b 0.042b 1.8 
(S,R)-2a  Et 0.014  0.25  17.9  
(S,R)-2b Me 0.087 0.5 5.7 
(S,R)-2c  HOCH2CH2 0.068  0.27  4.0 
(S,R)-2d  MeOCH2CH2 0.037  0.10 2.7  
(S,R)-2e  CF3CH2CH2 0.21  0.12  0.57  
(S,R)-2f  (CH3)2CHCH2 0.5 1.3  2.6  
a Selectivity factor of Plm IV/Cat D inhibition;  b Data from literature11 
 Fig. 2. Docking models of compounds (S,R)-2e and (S,R)-3d in crystal structures of 
Plm IV and Cat D  
 
We further explored N-monosubstituted amide analogues (S,R)-3a-m (see Section 2.3 
for synthesis). The best compounds in this series showed similar Plm IV inhibition 
potency compared to the most potent N,N-disubstituted amides (S,R)-2. Gratifyingly, 
these appeared to be less potent Cat D inhibitors, leading to improved selectivity 
factors. The removal of one N-substituent was more beneficial for compounds with 
larger or branched substituents (e.g. (S,R)-2e and (S,R)-2d compared to (S,R)-3d and 
(S,R)-3f) while for compounds bearing smaller substituents a slight decrease in Plm 
IV inhibitory activity was observed e.g. (S,R)-1b (Table 2) compared to (S,R)-1d 
(Table 3). The docking studies suggested that the introduction of a hydrogen bond 
donor (inhibitors (S,R)-3c,e,i,j,) or hydrogen bond acceptor ((S,R)-3a,l,f) group in the 
S3 sub-pocket substituents could potentially enable additional electrostatic 
interactions with electron-rich functional groups in this pocket. Hydrogen bond donor 
groups could interact with Asn13 and Leu14 backbone carbonyl in Plm IV; and 
Asp323, Tyr15, Gln14 and Ala13 in CatD, whereas for the hydrogen bond acceptors 
the most likely interactions are with Asn13 in Plm IV and Gln14 in Cat D (Fig. S1, 
see supporting information). Although the introduction of hydrogen bond donor or 
acceptor groups in the S3 sub-pocket occupying substituent reduced Plm IV inhibition 
activity (up to 2 times if comparing 1b and 3a), it also produced the most selective 
ligand in this series - (S,R)-3a, as the activity decrease for Cat D is even higher (up to 
19 times if comparing (S,R)-1b and (S,R)-3a). The docking studies suggest that the 
relatively higher drop in activity against Cat D for the compounds bearing the 
hydrogen bond donor or acceptor groups is due to an unfilled hydrophobic sub-pocket 
(resulting in an entropic penalty of solvating the non-polar sub-pocket). That is, the 
position of the amide substituent remains the same in both enzymes due to additional 
interactions with aforementioned residues (Fig.3), but by doing so it creates a 
situation where the Cat D hydrophobic sub-pocket is filled with water resulting in an 
entropic penalty and reduced Cat D inhibition activity. 
 
 
Fig. 3. Docking models of compound 3a in complex with Plm IV and Cat D. 
 
Despite varying hydrogen bond donor and acceptor groups in the S3 sub-pocket 
filling substituents, docking studies also suggest that the main factor affecting Plm IV 
and Cat D inhibition potency is the size and shape of the substituent; branched and 
long substituents cannot fit into the narrow S3 recess of Cat D whereas the open S3 
sub-pocket of Plm IV can accommodate such substituents. The weakest inhibitor of 
the N-mono-substituted amide analogues was compound (S,R)-3g. This could be 
explained by the protonated amine group as the amide substituent which, according to 
the docking studies, tends to form hydrogen bonds and ionic interactions with 
residues outside of the S3 sub-pocket. Altogether these results indicate that the 
selectivity against Cat D can be improved by targeting the S3 sub-pocket with mono-
substituted amide moieties containing linear or branched hydrophobic groups. 
  
Table 3. SAR of N-mono-substituted amide analogues (S,R)-1d, 3a-m  
 
Comp. R IC50 
Plm IV,  
IC50 
Cat D,  
Sa 
(S,R)-1d n-Pr 0.038b 0.11b 2.9 
(S,R)-3a  MeOC(CH3)2CH2 0.048 2.1 43.8 
(S,R)-3b  c-PrCH2 0.030 0.76 25.3 
(S,R)-3c  HOCH2CH2CH2 0.093 2.25 24.2 
(S,R)-3d  CF3CH2CH2 0.024 0.58 24.2 
(S,R)-3e  HOC(CH3)2CH2 0.10 1.66 16.6 
(S,R)-3f  MeOCH2CH2 0.05 0.75 15.0 
(S,R)-3g  Me2NCH2CH2 0.36  4.8  13.3  
(S,R)-3h  t-BuCH2 0.027  0.40  14.8  
(S,R)-3i  HOCH2C(CH3)2 0.12 1.46 12.2 
(S,R)-3j  HOCH2CH2 0.21 1.42 6.8 
(S,R)-3k  PhCH2 0.038  0.22  5.8  
(S,R)-3l  t-BuOCH2CH2  0.031 0.15 4.8 
(S,R)-3m  c-HexCH2 0.09 0.15 1.7 
a Selectivity factor of Plm IV/Cat D inhibition; b Data from literature11 
 
The S4 sub-pocket is another inhibitor binding region which is notably distinct 
between Plm IV and Cat D (Fig. 1A). Although predominantly hydrophobic in both 
enzymes, the S4 sub-pocket of Plm IV is flatter and more solvent exposed. Therefore, 
we investigated SAR for substituents occupying the S4 sub-pocket in the series of 
compounds (S,R)-4a-g (see Section 2.3. for synthesis). Installation of an N,N-
dipropylamide group (compound (S,R)-4g) resulted in practically unchanged Plm IV 
inhibitory activity compared to parent compound 1b, however this was paralleled by a 
more than 15-fold drop in activity against Cat D resulting in improvement of the 
selectivity factor. Installation of fluorine or removal of the S4 filling substituent 
provided compounds 4b,c with slightly decreased Plm IV inhibitory potency, whereas 
inhibition of Cat D was considerably lower which again improved the selectivity 
factor. Installation of chlorine in the benzene ring (compound 4d) improved the 
activity for both Plm IV and Cat D. Cyano, methyl and trifluoromethyl groups in the 
S4 sub-pocket (compounds 4a,e-f) made less difference for inhibitor binding to Plm 
IV and  Cat D.  Collectively, these effects of S4 occupying substituents are difficult to 
explain from our molecular modelling data, and presumably arise from an interplay of 
hydrophobic and polar non-covalent interactions.  
 
Table 4. SAR of phenylgroup substitution in analogues 1b,c, 4a-g  
 
Comp. R IC50 
Plm IV,  
IC50 
Cat D,  
Sa 
(S,R)-1b  1-piperidinyl 0.024b 0.042b 1.8 
(S,R)-1c  Ph 0.006b 0.054b 9.0 
(S,R)-4a  Me 0.023  0.21  9.1  
(S,R)-4b  H 0.058 1.15 19.8 
(S,R)-4c  F 0.050 1.0 20 
(S,R)-4d  Cl 0.008 0.096 12.0 
(S,R)-4e CF3 0.015  0.067  4.5  
(S,R)-4f  CN 0.059 0.56 9.5 
(S,R)-4g  (n-Pr)2NC(=O) 0.018 0.7 38.9 
a Selectivity factor of Plm IV/Cat D inhibition; b Data from literature11 
 
Considering that the lack of an S4 occupying substituent considerably improves 
selectivity against Cat D, analogues (S,R)-5a,b of the most  potent N-mono-
substituted amide inhibitors (S,R)-3d,h  were prepared and tested (Table 5, see 
Section 2.3. for synthesis). As expected, a slight drop in Plm IV inhibitory potency 
was observed; however the modifications appeared to be additive for a considerable 
improvement in the selectivity factor. 
 
Table 5. Combining selectivity inducing structural motives in analogues (S,R)-5a,b  
 
Comp. R 
IC50 
Plm IV,  
IC50 
Cat D,  
Sa 
(S,R)-5a t-BuCH2 0.076 3.8 50.0 
(S,R)-5b CF3CH2CH2 0.15 4.9 32.6 
a Selectivity factor of Plm IV/Cat D inhibition 
 
2.2. Relation of Plm subtype inhibition with P. falciparum growth inhibition. 
The capacity to inhibit growth in vitro of asexual blood stage P. falciparum was 
determined for selected compounds (S,R)-2a,3a,b,d,h,4b,c,g,5a,b (Table 6). In all 
cases, the compounds showed strong growth inhibitory potency with EC50 values in 
the low nanomolar range. Inhibitory activity against Plm I, Plm II and Plm IV was 
determined for the same compounds. This revealed no correlation between inhibitory 
potency in the parasite growth assay and inhibition of Plm I and II enzyme activity. In 
contrast, there was a much better correlation between parasite growth inhibition 
potency and Plm IV inhibition potency, although even here there were some notable 
exceptions; for instance, the most potent growth inhibitory compound, (S,R)-4b, was a 
3-fold weaker inhibitor of Plm IV than compound (S,R)-4g, yet showed a 20-fold 
better inhibition of parasite growth than (S,R)-4g.  
 
 
 
 
 
Table 6.  Plm I, II, IV inhibition and  P. falciparum growth inhibition activity of  
selected compounds 
 
Comp. 
IC50 
Plm I,  
IC50 
Plm II,  
IC50 
Plm IV,  
Sa EC50
b 
Pf Growth, n 
(S,R)-2a  0.8 0.16  0.014  17.9 1.5 
(S,R)-3a  7.4 5.4 0.048 43.8 2.0 
(S,R)-3b  1.8 0.5 0.030 25.3 1.8 
(S,R)-3d  2.5 2.2 0.024 24.2 2.0 
(S,R)-3h  2.0  0.85  0.027  14.8 6.0 
(S,R)-4b  3.1 1.7 0.058 19.8 0.3 
(S,R)-4c  1.1 1.1 0.050 20 1.5 
(S,R)-4g  0.78 0.27 0.018 38.9 6.0 
(S,R)-5a  5.6 7.1 0.076 50.0 2.0 
(S,R)-5b  10.3 10.4 0.15 32.6 6.0 
a Selectivity factor of Plm IV/Cat D inhibition; bThe EC50 values for P. falciparum 
growth were determined using a SYBR Green-based assay with an incubation time of 
96 h (2 erythrocytic cycles). Samples were each measured in triplicate, in 2 separate 
biological assays. Compound TCMDC-13467411,20 was used as a positive control (see 
Supporting Information). 
 
These results implied that the important parasite target(s) engaged by the growth 
inhibitory compounds are not the hemoglobinase plasmepsins. Recent reports have 
shown that inhibitors of the non-hemoglobinase plasmepsins Plm IX and Plm X 
(which are structurally similar to Plm I, II and IV) can potently block parasite 
replication.29,30  A key biological function of Plm X is the proteolytic maturation of 
SUB1, a parasite subtilisin-like serine protease that plays an essential role in 
regulating parasite release (egress) from the infected host erythrocyte.38 SUB1 
maturation comprises 2 steps in which the initial ~82 kDa pre-proenzyme is cleaved 
to form first a 54 kDa protein (p54) then a 47 kDa terminal product (p47) which 
accumulates during the latter ~12 h of intra-erythrocytic parasite development. Whilst 
the first SUB1 processing step is autocatalytic, the second p54-to-p47 step is believed 
to be mediated by Plm X.29, 30 We used a Western blot-based assay to examine the 
effects of selected compounds (S,R)-2a, (S,R)-4b and (S,R)-4c on both SUB1 
maturation and parasite egress (Fig. 4).  
  
 
Fig.4. Inhibition of P. falciparum SUB1 maturation and egress by selected 
compounds indicates that they target Plm X. (A) Synchronous cultures of immature 
intracellular parasites were treated for ~8 h with compounds  (S,R)-2a or (S,R)-4b,c 
(10 nM), or vehicle only (DMSO, 1% v/v), or the cGMP-dependent protein kinase 
inhibitor (4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imidazo[1,2-α]pyridine-3-
yl]pyrimidin-2-amine (compound 2; C2, 2 M) which inhibits egress but not SUB1 
maturation. Extracts of the parasites were then analyzed by Western blot, probing 
with an antibody to SUB1. The positions of migration of the SUB1 p54 and p47 
forms (green arrow) are indicated. The schematic below indicates the mode by which 
Plm X converts SUB1 p54 to the terminal p47 form. (B) Parasites treated for ~ 24 h as 
in (A) were transferred to fresh medium containing the various compounds and 
allowed to undergo egress for 4 h before the culture supernatants were analysed by 
Western blot, probing with antibodies to the parasite protein SERA5. The positions of 
migration of the SERA5 precursor, a processing intermediate and the terminal P50 
form (green arrow) are indicated. The schematic below indicates the mode by which 
SUB1 converts the SERA5 precursor to the P50 form.  
 
Egress was quantified by measuring the release of a soluble parasite protein called 
SERA5 into parasite culture supernatants. SERA5 is also a SUB1 substrate, and is 
generally released in a P50 form that results from SUB1-mediated cleavage of a larger 
precursor. Release of correctly processed SERA5 P50 is therefore an indicator of both 
SUB1 activity and efficiency of egress. As shown in Fig. 4A, treatment of developing 
intracellular parasites with the three Plm inhibitors (S,R)-2a, (S,R)-4b  and (S,R)-4c 
resulted in a relative enrichment of the p54 form of SUB1, indicating inhibition of 
conversion of p54 to the terminal p47 form. Analysis of culture supernatants from 
treated parasites allowed to proceed to egress (Fig. 4B) showed that  compounds 
(S,R)-4b and (S,R)-4c both produced a clear reduction in SERA5 P50 release, whilst 
all three compounds produced an increase in the release of SERA5 precursor or 
processing intermediates, indicating defects in egress and SERA5 processing. These 
results strongly suggest that the mechanism of parasite growth inhibition by 
compounds (S,R)-4b and (S,R)-4c (as well as possibly (S,R)-2a) involves Plm X 
inhibition, since the effects on egress were linked to inhibition of SUB1 maturation 
and its enzymatic activity against an endogenous substrate. Given their structural 
similarity, it is likely that the other compounds 3a,b,d,h, 4g and 5a,b exerting potency 
in the parasite growth assay (Table 6) also target Plm X.  
 
2.3. Synthesis of inhibitors (S,R)–2-5 
Plm inhibitors (S,R)–2-5 were synthesized from substituted benzoic acids 15, 17 and 
19 and either enantiomerically pure amino alcohol (R,S)–11 or the corresponding 
racemate rac-11 (Schemes 1-5). Inhibitors (S,R)–2b-e, (S,R)–3a,c,e-g,i,j,l,m, (S,R)–
4c,f,g and (S,R)–5a,b were obtained from enantiomerically pure amino alcohol (R,S)–
11, whereas targets 2a,f, 3b,d,h,k and 4a,b,d,e were obtained as mixtures of 
stereoisomers from racemic alcohol rac-11. Enantiomerically pure inhibitors (S,R)–
2a,f, (S,R)–3b,d,h,k and (S,R)–4a,b,d,e were obtained by separation of diastereomers 
using chromatography on silica gel, followed by separation of enantiomers using the 
chromatography on a chiral stationary phase. 
Synthesis of aminoalcohol 11 commenced with N-Boc protection of rac-6 (Scheme 
1). Dihydroxylation of the resulting carbamate rac–7 with AD-mix- afforded diol 8 
as a 2:3 mixture of syn:anti diastereomers and a 2:1 mixture of enantiomers. 
Enantiomerically pure diol (S,S)–8 was obtained by an initial separation of syn/anti 
diastereomers using chromatography on silica gel, followed by separation of syn–8 
enantiomers by chromatography on a chiral stationary phase. The major enantiomer 
turned out to be the desired diol (S,S)–8 as evidenced by comparison of optical 
rotation data with that from the literature.39 Conversion of (S,S)–8 into epoxide (S,S)–
9 under Mitsunobu conditions was followed by aminolysis with 2-(3-
methoxyphenyl)propan-2-amine11 to afford N-Boc protected amino alcohol (S,R)–10. 
Finally, the cleavage of N-Boc protecting group yielded amino alcohol (R,S)–11. 
Benzoic acids 15a-s were prepared from dimethyl 5-bromoisophthalate (Scheme 2). 
Pd-catalyzed amination with piperidine afforded 12a, which was hydrolysed to 
isophthalic monoester 13a under basic conditions. Subsequent HBTU-mediated 
condensation with amines afforded amides 14a-s, which were hydrolysed to benzoic 
acids 15a-s.  
 
 
Scheme 1. Synthesis of amino alcohol intermediate (R,S)–11. Reagents and 
conditions: a) Boc2O (1.25 equiv), NEt3 (2 equiv), DCM, rt, 2 h, 87%. b) AD-mix-α 
(1 equiv), 1:1 (v/v) t-BuOH:water, rt, 20 h. c) preparative HPLC on chiral stationary 
phase (Chiralpack-ID), 25% in two steps. d) Ph3P (1.1 equiv), DEAD (1.1 equiv), 
CHCl3, 85 
oC, 48 h, 64%. e) 2-(3-Methoxyphenyl)propan-2-amine11 (1.05 equiv), i-
PrOH, 70 oC, 40 h, 73%. f) 4 M HCl in dioxane, rt, 6h, 99%. 
 
 
Scheme 2. Synthesis of Plm inhibitors (S,R)–2a-f and (S,R)–3a-m. Reagents and 
conditions: a) piperidine (1 equiv), Pd(OAc)2 (5 mol%), rac-BINAP (5 mol%), 
Cs2CO3 (1.5 equiv), toluene, 100 
oC, 18 h, 88%. b) General procedure A: aqueous 1 
M NaOH (1 equiv), MeOH, rt, 16 h. c) General procedure B: R1R2NH (1.2 equiv), 
HBTU (1 equiv), NEt3 (2 equiv), DMF, rt, 2 h. d) General procedure C: aqueous 1 M 
NaOH (1.5 equiv), MeOH, 50 oC, 18 h. e) General procedure D: amino alcohol (R,S)–
11 (1.0 equiv), HBTU (1.0 equiv), NEt3 (4 equiv), DMF, rt, 16 h. f) amino alcohol 
rac–11 (1.0 equiv), HBTU (1.0 equiv), NEt3 (4 equiv), DMF, rt, 16 h; then separation 
of enantiomers by HPLC on chiral stationary phase (Chiralpack-ID). 
 
 
Table 7. Substitution pattern of compounds in Scheme 2. 
R1 R2 No. No.  No. Comments 
Et Et 14a 15a (S,R)-2a from rac–11 (step f) 
Me Me 14b 15b (S,R)-2b  
HOCH2CH2 HOCH2CH2 14c 15c (S,R)-2c  
MeOCH2CH2 MeOCH2CH2 14d 15d (S,R)-2d  
CF3CH2CH2 CF3CH2CH2 14e 15e (S,R)-2e  
(CH3)2CHCH2 (CH3)2CHCH2 14f 15f (S,R)-2f from rac–11 (step f) 
H MeOC(CH3)2CH2 14g 15g (S,R)-3a  
H c-PrCH2 14h 15h (S,R)-3b from rac–11 (step f) 
H HOCH2CH2CH2 14i 15i (S,R)-3c  
H CF3CH2CH2 14j 15j (S,R)-3d from rac–11 (step f) 
H HOC(CH3)2CH2 14k 15k (S,R)-3e  
H MeOCH2CH2 14l 15l (S,R)-3f  
H Me2NCH2CH2 14m 15m (S,R)-3g  
H t-BuCH2 14n 15n (S,R)-3h from rac–11 (step f) 
H HOCH2C(CH3)2 14o 15o (S,R)-3i  
H HOCH2CH2 14p 15p (S,R)-3j  
H PhCH2 14q 15q (S,R)-3k from rac–11 (step f) 
H t-BuOCH2CH2 14r 15r (S,R)-3l  
H c-HexCH2 14s 15s (S,R)-3m  
 
Similar synthetic approach was also used for the preparation of acids 17b-i (Scheme 
3). Accordingly, monoesters 13c-f were obtained from commercially available 
dimethyl isophthates. The synthesis of methyl ester 13b required an initial Pd-
catalyzed alkylation of dimethyl 5-bromoisophthalate with methylboronic acid, 
followed by hydrolysis of one of the two ester moieties. Benzoic acids 13b-f were 
converted into amides 16b-f and ester moieties were hydrolysed to afford acids 17b-f. 
Benzoic acid 17h was obtained directly from trifluoromethyl isophthalic acid and n-
Pr2NH in the presence of HBTU, whereas the synthesis of 17i was accomplished by 
Cu(I)-catalyzed substitution of bromide in benzoic acid 17c for cyano group (Scheme 
3).  
Scheme 3. Synthesis of Plm inhibitors (S,R)–4a-f. Reagents and conditions: a) 
MeB(OH)2 (1.2 equiv), Pd(dppf)Cl2xCH2Cl2 (5 mol%), K3PO4 (3 equiv), toluene, 90 
°C, 18 h. b) General procedure A: aqueous 1 M NaOH (1 equiv), MeOH, rt, 16 h. c) 
General procedure B: (n-Pr)2NH (1.2 equiv), HBTU (1 equiv), NEt3 (2 equiv), DMF, 
rt, 2 h. d)  General procedure C: aqueous 1 M NaOH (1.5 equiv), MeOH, 50 
oC, 18 h. 
e) CuCN (2 equiv), NMP, 160 oC, 6 h. f) General procedure D: amino alcohol (R,S)–
11 (1.0 equiv), HBTU (1.0 equiv), NEt3 (4 equiv), DMF, rt, 16 h. g) amino alcohol 
rac–11 (1.0 equiv), HBTU (1.0 equiv), NEt3 (4 equiv), DMF, rt, 16 h; then separation 
of enantiomers by HPLC on chiral stationary phase (Chiralpack-ID).   
 
  
Table 8. Substitution pattern of compounds in Scheme 3. 
R No. No. No. No. No. Comments 
Me 12b 13b 16b 17b (S,R)–4a from rac–11 (step g) 
Br - 13c 16c 17c -  
H - 13d 16d 17d (S,R)–4b from rac–11 (step g) 
F - 13e 16e 17e (S,R)–4c  
Cl - 13f 16f 17f (S,R)–4d from rac–11 (step g) 
CF3 - - - 17h (S,R)–4e from rac–11 (step g) 
CN - - - 17i (S,R)–4f  
 
Synthesis of benzoic acid 17g (Scheme 4) commenced with hydrolysis of 
commercially available dimethyl iodo-isophthalate to the corresponding isophthalic 
acid 18, followed by Pd-catalyzed methoxycarbonylation40 to afford ester 13g. 
Subsequent conversion to diamide 16g in the presence of HBTU was followed by 
ester hydrolysis to form benzoic acid 17g (Scheme 4). The amide bond formation-
hydrolysis sequence was also used for the preparation of benzoic acids 19a,b (Scheme 
5).  
 
Scheme 4. Synthesis of Plm inhibitor (S,R)–4g. Reagents and conditions: a) aqueous 
1 N NaOH (3 equiv), MeOH, 40 oC, 18 h. b) Pd(dppf)Cl2xCH2Cl2 (10 mol%), NEt3 
(2.2 equiv), CO (70 psi), MeOH, 100 oC, 18 h. c) General procedure B: (n-Pr)2NH 
(2.2 equiv), HBTU (2 equiv), NEt3 (4 equiv), DMF, rt, 2 h. d)  General procedure C: 
aqueous 1 M NaOH (1.5 equiv), MeOH, 50 oC, 18 h. e) General procedure D: amino 
alcohol (R,S)–11 (1.0 equiv), HBTU (1.0 equiv), NEt3 (4 equiv), DMF, rt, 16 h. 
 Scheme 5. Synthesis of Plm inhibitors 5a,b. Reagents and conditions: a) General 
procedure B: (n-Pr)2NH (1.2 equiv), HBTU (1 equiv), NEt3 (2 equiv), DMF, rt, 2 h. b) 
General procedure C: aqueous 1 M NaOH (1.5 equiv), MeOH, 50 oC, 18 h. c) General 
procedure D: amino alcohol (R,S)–11 (1.0 equiv), HBTU (1.0 equiv), NEt3 (4 equiv), 
DMF, rt, 16 h.  
Summary  
The optimization of hydroxyethylamine based Plm inhibitors was performed with the 
aim of improving selectivity against the related human aspartic protease Cat D. The 
studies were performed using Plm IV as a readily accessible model protein, the 
inhibition of which was previously found to correlate with Plasmodium falciparum 
growth inhibition. Based on sequence alignment of Plm IV and Cat D, putative 
selectivity inducing structural motifs were sought in S3 and S4 sub-pocket-occupying 
substituents of the inhibitors. Installation of an S3 sub-pocket targeting mono-
substituted amide moiety in compounds (S,R)-3 containing linear or branched 
hydrophobic groups resulted in up to 40-fold selectivity (compound (S,R)-3a) against 
Cat D. Plm IV inhibitors (S,R)-4b,c with no substituents or fluorine targeting the S4 
sub-pocket led to 20-fold selectivity against Cat D, though with some loss of Plm IV 
inhibition potency. Surprisingly, installation of amide as the S4 sub-pocket filling 
group in compound (S,R)-4g  resulted in potent Plm IV inhibition with almost 40-fold 
selectivity against Cat D. Selectivity-inducing factors in S3 and S4 positions were 
additive as evidenced by compound (S,R)-5a (50-fold selectivity).  Determination of 
P. falciparum growth inhibition potency for ten of the new Plm inhibitors showed 
them to display activities in the low nanomolar range. The potent anti-malarial 
activity did not correlate with the relatively weak inhibition of Plm I and II,  whilst in 
contrast there was a much better correlation with Plm IV inhibition. More detailed 
investigation of the mechanism of action of the selected compounds showed that they 
interfered with parasite egress and maturation of the parasite serine protease SUB1, 
indicating a strong link between anti-malarial activity and inhibition of the non-
hemoglobinase plasmepsin and SUB1 maturase Plm X.  Future studies should clarify 
whether cooperative Plm IV and Plm X inhibition or only Plm X inhibition is 
necessary to achieve optimal anti-malarial activity. 
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